Group 1 - WuXi AppTec (02126) announced the grant of a total of 4.2045 million stock options to its Chairman, CEO, and Executive Director, Mr. Min Liu, on September 16, 2025, in accordance with the terms of the incentive plan adopted after its initial public offering on October 14, 2020 [1]

Group 1 - WuXi AppTec (02126) announced the grant of a total of 4.2045 million stock options to Mr. Liu Min, the Chairman, CEO, and Executive Director of the company, on September 16, 2025 [1] - The stock options were granted under the terms of the incentive plan adopted after the company's initial public offering on October 14, 2020 [1]

JW (Cayman) Therapeutics Co. Ltd 藥明巨諾（開曼）有限公司* （於開曼群島註冊成立的有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 （股份代號：2126） 授出購股權 本 公 告 由 藥 明 巨 諾（開 曼）有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本 集 團」）根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第 17.06A、17.06B及17.06C條作出。 本公司董事（「董事」）會（「董事會」）宣佈，於2025年9月16日，根據2020年10月14 日採納的本公司首次公開發售後激勵計劃（「首次公開發售後激勵計劃」）的條 款將合共4,204,490份購股權（「購股權」）授予本公司主席、行政總裁兼執行董事 劉敏先生（「劉先生」）。 上市規則的涵義 由於向劉先生授予購股權會導致劉先生於直至授出日期（包括該日）止12個月 期間內獲授的所有購股權及受限制股份單位（「受限 ...

Market Overview - The A-share market experienced slight fluctuations, with the Shanghai Composite Index closing down by 0.12%, the Shenzhen Component Index down by 0.43%, and the ChiNext Index down by 1.09% [5] - A total of 1,926 stocks rose, while 3,373 stocks fell, indicating a challenging market environment [6] Stock Performance - The total trading volume reached 25,483.12 billion, with a total of 5,429 stocks traded [7] - Notable sectors included the storage chip sector, which saw significant gains, with companies like Jingzhida and Demingli hitting the daily limit [8] - The storage product prices are expected to rise by 20% to 30%, following a previous announcement of a 10% increase by SanDisk [8] Sector Highlights - The non-ferrous metals sector showed strength, with companies like Northern Copper and Shengda Resources also hitting the daily limit [10] - Real estate stocks saw a surge, with Rongsheng Development and Huaxia Happiness reaching their daily limit [12] Financial Sector - The financial sector faced declines, with major banks like Pudong Development Bank and China Merchants Bank seeing drops of over 3% [13][12] - Securities firms also experienced downturns, with Guohai Securities and Dongfang Securities both declining [14] Hong Kong Market - The Hong Kong stock market saw a rise, with major indices increasing by over 1% [15] - Alibaba's stock surged by 5.37%, attributed to the introduction of self-developed chips for AI model training [16] - Evergrande Property experienced a significant increase of over 23% due to potential acquisition interest [16] Notable Company Developments - Yaojie Ankang's stock price skyrocketed by over 120% following the announcement of clinical trial approval for its core product [19]

Group 1 - A-share market experienced a significant rally, with the ChiNext Index surpassing 3000 points for the first time in over three years, and the Sci-Tech 50 Index seeing an intraday increase of over 5% [2][4] - Key stocks in the Sci-Tech board, such as Haiguang Information and Cambricon Technologies, saw substantial gains, with Haiguang Information hitting a historical high of 220.84 yuan and a market capitalization exceeding 510 billion yuan [4][5] - The ChiNext Index recorded a rise of 4.31%, reaching 3029.58 points, with a total trading volume of approximately 419.48 billion yuan [5] Group 2 - The Hong Kong stock market showed a slight decline in the morning, with notable stocks like Semiconductor Manufacturing International Corporation and China Hongqiao Group performing well, while others like CSPC Pharmaceutical Group faced losses [6] - In the Hong Kong market, Longi Green Energy and other stocks saw significant intraday increases, with Longi Green Energy rising over 19% [6] - The announcement of clinical trial results for Tinengotinib by Yaojie Ankang-B indicated promising outcomes for breast cancer treatment, contributing to the stock's strong performance [7]

Market Overview - The A-share market opened with mixed results, with the Shanghai Composite Index down by 0.16%, the Shenzhen Component Index up by 0.11%, and the ChiNext Index up by 0.46% [3][4] - The Hang Seng Index opened down by 0.81%, and the Hang Seng Tech Index fell by 0.97% [6][7] Pharmaceutical Sector Performance - The innovative drug concept stocks experienced significant declines, with BeiGene falling over 10%, WuXi AppTec and Tigermed down over 7%, and several other companies like Hengrui Medicine, Junshi Biosciences, and Kelun Pharmaceutical dropping over 5% [2][6] - The pharmaceutical sector as a whole saw a downturn, with various sub-sectors such as medical services, weight loss drugs, and CRO concepts all reporting negative performance, with declines ranging from -1.13% to -1.99% [5] Notable Stock Movements - Specific stocks such as Hansoh Pharmaceutical and WuXi Biologics dropped over 10%, while Jiangsu Hengrui Medicine and Junshi Biosciences also faced significant losses [6] - Conversely, some stocks like Jiujiuwang Pharmaceutical saw a rise of 5% despite the overall market trend [6]

Market Overview - The innovative drug concept stocks opened significantly lower, with BeiGene dropping over 10%, WuXi AppTec and Tigermed down over 7%, and several other companies like HengRui Medicine, Junshi Biosciences, and Kelun Pharmaceutical falling over 5% [3][4]. - The A-share market showed mixed results, with the Shanghai Composite Index down 0.16%, while the Shenzhen Component Index rose 0.11% and the ChiNext Index increased by 0.46% [4][5]. Sector Performance - The healthcare sector experienced a decline, with various sub-sectors such as medical services, CRO concepts, and innovative drugs all showing negative performance, with declines ranging from -1.99% to -1.44% [6]. - The Hong Kong market also opened lower, with the Hang Seng Index down 0.81% and the Hang Seng Tech Index falling 0.97%. Pharmaceutical stocks in Hong Kong saw significant drops, with companies like Hansoh Pharmaceutical and WuXi Biologics declining over 10% [6][7]. Notable Stocks - Specific stocks highlighted include BeiGene, WuXi AppTec, and Tigermed, which are part of the innovative drug sector and faced substantial declines in their stock prices [3][4]. - In the Hong Kong market, Hansoh Pharmaceutical and WuXi Biologics were noted for their significant drops, while a few stocks like Jiujiuwang Technology showed resilience with a 5% increase [6][7].

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: JW (Cayman) Therapeutics Co. Ltd 藥明巨諾（開曼）有限公司* 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02126 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | ...

Core Viewpoint - The company reported better-than-expected reduction in operating losses for 1H25, driven by cost control and licensing agreements [1][2] Financial Performance - Revenue for 1H25 reached 106 million yuan, a year-on-year increase of 22.5% - The net loss attributable to shareholders was 267 million yuan, with an operating loss of 114 million yuan after excluding impairment impacts, showing a reduction in losses of 126.5 million yuan compared to the same period last year [1] - The gross margin for product sales improved to 51.1%, up 0.7 percentage points year-on-year, while the sales expense ratio decreased by 15.7 percentage points to 72.0% [1] Development Trends - The company achieved stable sales for its main product, Benodac, in 1H25, and entered a licensing agreement with Juno for JW sLVV production technology, with a payment of up to 10 million USD expected to enhance performance [1] - The company disclosed a new CD19/20 dual-target CAR-T pipeline, with data expected by the end of the year, and initiated IIT research for JWCAR201 in hematological malignancies and autoimmune diseases [1] Clinical Trials - The company started a Phase I clinical trial for systemic lupus erythematosus (SLE) in May 2024, with patient enrollment completed by 1Q25, indicating a first-mover advantage in CAR-T treatment for SLE in China [2] Profit Forecast and Valuation - Due to the better-than-expected reduction in operating losses, the company raised its 2025 net profit forecast from a loss of 609 million yuan to a loss of 427 million yuan, and introduced a 2026 forecast of a loss of 320 million yuan [2] - The target price was increased by 151.7% to 6.04 HKD, indicating a potential upside of 19.6% from the current stock price [2]

Core Viewpoint - CICC's research report indicates that WuXi AppTec's revenue for the first half of the year reached 106 million yuan, representing a year-on-year increase of 22.5%, with better-than-expected loss reduction [1] Group 1 - CICC maintains an "outperforming the industry" rating for WuXi AppTec, considering the company's loss reduction, progress in SLE and early pipeline, along with the upward adjustment of industry valuation [1] - The target price for WuXi AppTec has been raised by 151.7% to 6.04 HKD [1]